245 related articles for article (PubMed ID: 37029381)
1. CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022.
Huang R; Wen Q; Zhang X
J Hematol Oncol; 2023 Apr; 16(1):35. PubMed ID: 37029381
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.
Abbasi S; Totmaj MA; Abbasi M; Hajazimian S; Goleij P; Behroozi J; Shademan B; Isazadeh A; Baradaran B
Cancer Med; 2023 Apr; 12(7):7844-7858. PubMed ID: 36583504
[TBL] [Abstract][Full Text] [Related]
3. Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting.
Wang JN; Gu T; Hu Y; Huang H
Exp Hematol Oncol; 2022 Sep; 11(1):61. PubMed ID: 36153595
[TBL] [Abstract][Full Text] [Related]
4. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H
Front Immunol; 2022; 13():847008. PubMed ID: 35464442
[TBL] [Abstract][Full Text] [Related]
5. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies.
Tanaka J
Hematol Oncol; 2021 Feb; 39(1):11-19. PubMed ID: 32905618
[TBL] [Abstract][Full Text] [Related]
7. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
Yang Z; Wang Y
Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
[TBL] [Abstract][Full Text] [Related]
8. Engineering the next generation of CAR-NK immunotherapies.
Biederstädt A; Rezvani K
Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
[TBL] [Abstract][Full Text] [Related]
9. CAR-NK cell in cancer immunotherapy; A promising frontier.
Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
[TBL] [Abstract][Full Text] [Related]
10. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.
Marofi F; Saleh MM; Rahman HS; Suksatan W; Al-Gazally ME; Abdelbasset WK; Thangavelu L; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Pathak Y; Naimi A; Baradaran B; Nikoo M; Khiavi FM
Stem Cell Res Ther; 2021 Jul; 12(1):374. PubMed ID: 34215336
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and clinical studies of CAR-NK-cell therapies for malignancies.
Li H; Song W; Li Z; Zhang M
Front Immunol; 2022; 13():992232. PubMed ID: 36353643
[TBL] [Abstract][Full Text] [Related]
12. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
Khan AN; Asija S; Pendhari J; Purwar R
Eur J Haematol; 2024 Jan; 112(1):6-18. PubMed ID: 37545253
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
14. Engineering Natural Killer Cells for Cancer Immunotherapy.
Rezvani K; Rouce R; Liu E; Shpall E
Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
[TBL] [Abstract][Full Text] [Related]
15. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
16. [Progress in Chimeric Antigen Receptor-Modified Natural Killer Cells for Multiple Myeloma].
Tang WJ; Li Y; Zheng YH; Zhang L; Niu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Apr; 45(2):290-297. PubMed ID: 37157078
[TBL] [Abstract][Full Text] [Related]
17. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
18. [Research Progress of Chimeric Antigen Receptor Modified NK Cells in the Treatment of Acute Myeloid Leukemia --Review].
Peng XR; Cheng J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1905-1909. PubMed ID: 38071081
[TBL] [Abstract][Full Text] [Related]
19. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
[TBL] [Abstract][Full Text] [Related]
20. NK cell therapy in relapsed refractory multiple myeloma.
Roshandel E; Ghaffari-Nazari H; Mohammadian M; Salimi M; Abroun S; Mirfakhraie R; Hajifathali A
Clin Immunol; 2023 Jan; 246():109168. PubMed ID: 36415020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
